Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Laserscope

This article was originally published in The Gray Sheet

Executive Summary

Laserscope Aura: Firm is gearing up to begin shipments of the surgical and dermatological laser system in October following April 510(k) clearance by FDA. The device, which fills out the firm's exisiting line of lasers with dermatologic applications including the Orion and 800 Series systems, will be targeted at the physician's office and outpatient surgery markets. In the dermatology area, Laserscope says the Aura can be used to treat "vascular lesions such as leg veins, hemangiomas, birth marks and facial spider veins, as well as benign occurrences such as brown sun spots, liver spots, skin tags, warts and moles." The device also can be used for ear, nose and throat applications, Laserscope says. The company plans to sell the system through its 30-person direct sales force in the U.S., U.K, and France, and through distributors in other countries. Aura can be used in combination with Laserscope's SmartScan microprocessor-controlled dermatologic scanning device, introduced last year, and will be priced between $49,000 and $70,000...

You may also be interested in...

ICER Partnering With Aetion To Scale Up Use Of RWE In Value Assessments

Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.

‘Highly Questionable’ GMP Compliance In Pakistan Prompts New Licensing System

Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.

Infographic: 20 Years Of Mega-Deals

The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019. 




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts